Dosing & Administration for Episodic Cluster Headache


Emgality offers a specific dose for adults with episodic cluster headache1

Recommended dosing with no titration required1a

300 mg administered as 3 consecutive subcutaneous injections of 100 mg each, at the onset of the cluster period, and then monthly until the end of the cluster period.1

  • 300 mg dose; this comes in 3 x 100 mg prefilled syringes
  • These 3 syringes are administered subcutaneously, one after another
  • Patients begin treatment at the onset of a cluster period
  • Patients take this 300 mg dose every month until their cluster period ends
Three 100 mg dose syringes

aThe Emgality prefilled syringe needle is 27 gauge x 1/2 inch.2

Hypothetical dosing example1

On average, Frank experiences approximately 2 cluster periods a year.

Frank hypothetical dosing example

Advise patients to1,3:

  • Store product refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect it from light until use
  • Check expiration date on product prior to use
Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis, angioedema, dyspnea, urticaria, and rash, have been reported with Emgality. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.


GZ HCP ISI 04JUN2019